课题基金 / 基金详情

APOL1 associated disease spectrum

APOL1 associated disease spectrum
APOL1相关疾病谱
批准号:
10683097
负责人:
KATALIN SUSZTAK
金额:
$53.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-12-21 至 2025-07-31

项目摘要

项目成果

KATALIN SUSZTAK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Each year, at least 1.7 million adults in the US develop sepsis and nearly 270,000 Americans die of sepsis. 1 in 3 patients who dies in a hospital has sepsis. African Americans have a 67% higher severe sepsis hospitalization rate and 20% more likely to die of sepsis compared to whites even after adjusting for co-variates. Close to 45% African American carry at least one APOL1 risk allele. Variants in APOL1 are thought to have arisen as a result of positive genetic selection, as they confer resistance against Trypanosome brucei rhodesiense, a parasite that causes African sleeping sickness. While having one risk variant imparts this crucial resistance against sleeping sickness, having two risk alleles significantly increases the risk of developing kidney disease. Recent genetic and mouse model studies indicate that APOL1 risk variant (RV) in endothelial cells might explain the increased sepsis susceptibility and severity in African Americans. Aim1. Define the role of RV APOL1 in sepsis in mouse models and patients. A. Characterize sepsis severity in mice with conditional inducible expression of RV and reference APOL1 in endothelial cells, kidney and liver cells. B. Examine the association between APOL1 RV genotype and sepsis incidence and severity in the Upenn (PMBB) and Vanderbilt (BioVU) Biobanks. C. Determine the association of plasma APOL1 level and sepsis severity in the MESSI cohort. Aim2. Define endothelial RV APOL1 induced pathology. A. Characterize RVAPOL1 endotheliopathy such as inflammation, permeability and coagulation changes using isogenic gene edited RV APOL1 human and mouse transgenic endothelial cells. B. Using single cell gene expression characterize changes associated with RV APOL1-induced endotheliopathy in vivo. C. Describe the cellular trafficking defect induced by RV APOL1 such as endocytosis, autophagy, and mitophagy in EC. Aim3. Determine whether pharmacological, or cell type specific genetic targeting of the inflammasome (NLRP3) and nucleotide sensing pathways (STING) alleviate endothelial RV APOL1 associated endotheliopathy and sepsis RV APOL1 is a critical determinant of health disparities affecting millions of people in the US. Our study will define the role endothelial of RV APOL1 in sepsis and could identify novel drugs to target RV APOL1
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.kint.2020.08.004
发表时间: 2020-11
期刊: KIDNEY INTERNATIONAL
影响因子: 19.6
作者: [Mukhi, Dhanunjay, Susztak, Katalin]
通讯作者: Susztak, Katalin
DOI: 10.1186/s13059-023-03159-6
发表时间: 2024-01-12
期刊: Genome biology
影响因子: 12.3
作者: []
通讯作者:
The role of cytosolic nucleotide sensors in inflammatory fibrosis
  • 批准号:
    10676311
  • 项目类别:
  • 资助金额:
    $49.84万
  • 财政年份:
    2022
  • 负责人:
    KATALIN SUSZTAK
  • 依托单位:
The role of cytosolic nucleotide sensors in inflammatory fibrosis
  • 批准号:
    10435065
  • 项目类别:
  • 资助金额:
    $50.91万
  • 财政年份:
    2022
  • 负责人:
    KATALIN SUSZTAK
  • 依托单位:
Molecular Precision Nephrology Core
  • 批准号:
    10529734
  • 项目类别:
  • 资助金额:
    $13.08万
  • 财政年份:
    2017
  • 负责人:
    KATALIN SUSZTAK
  • 依托单位:
Molecular Precision Nephrology Core
  • 批准号:
    10705304
  • 项目类别:
  • 资助金额:
    $13.08万
  • 财政年份:
    2017
  • 负责人:
    KATALIN SUSZTAK
  • 依托单位:
海外基金